作者: Junli Deng , Li Wang , Jie Ni , Julia Beretov , Valerie Wasinger
DOI: 10.1080/14789450.2016.1233065
关键词: Medicine 、 Biomarker (medicine) 、 Ovarian cancer 、 Biomarker discovery 、 Bioinformatics 、 Potential biomarkers 、 Proteomics 、 Chemotherapeutic response
摘要: ABSTRACTIntroduction: Chemoresistance is a major challenge to current ovarian cancer chemotherapy. It important identify biomarkers distinguish chemosensitive and chemoresistant patients.Areas covered: We review the medical literature, discuss MS-based technologies with respect summarize promising identified. In addition, challenges future perspectives of biomarker discovery research are explored. With employment mass spectrometry-based (MS-based) proteomics, has made great progress in last decade. Many potential were identified by proteomics technologies, some which have been validated for further extensive studies clinical settings.Expert commentary: The newly developing area may provide clue predicting chemotherapeutic response discover therapeutic targets paving way personalize...